0

    530125

    SAMRATPH

    img img img img
    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    SAMRAT PHARMACHEM LTD. Share Price Today

    Investment Returns

    Over 1 Month -6.65% Over 3 Months 5.73% Over 6 Months -5.94% Over 1 Year -36.69%
    demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    SAMRAT PHARMACHEM LTD. fundamentals


    • Market cap (Cr) [-]
    • P/E Ratio (TTM) [-]
    • Beta [-]
    • Book Value / share [-]
    • Return on equity [-]%
    • EPS (TTM) [-]
    • Dividend yield [-]%
    • Net profit/quarter (Cr) [-]
    info icon alternate text
    • Market cap (Cr) 69.00
    • P/E Ratio (TTM) -20.22
    • Beta 0.65
    • Book Value / share 220.66
    • Return on equity 10.39%
    • EPS (TTM) 0.00
    • Dividend yield [-]%
    • Net profit/quarter (Cr) -2.04
    info icon alternate text

    SAMRAT PHARMACHEM LTD. Financials

    • Key Results
    • Key Ratios
    • Balance sheet
    • Cash Flow
    • Competition
    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 71.77
    Operating Expense 73.34
    Net Profit -2.04
    Net Profit Margin (%) -2.84
    Earnings Per Share (EPS) -6.59
    EBITDA -1.54
    Effective Tax Rate (%) -8.55
    Particulars DEC 2025 (Values in Cr)
    Revenue 63.43
    Operating Expense 64.39
    Net Profit -0.46
    Net Profit Margin (%) -0.72
    Earnings Per Share (EPS) -1.49
    EBITDA -0.24
    Effective Tax Rate (%) 19.29
    Particulars SEP 2025 (Values in Cr)
    Revenue 78.87
    Operating Expense 79.67
    Net Profit -0.59
    Net Profit Margin (%) -0.74
    Earnings Per Share (EPS) -1.90
    EBITDA -0.31
    Effective Tax Rate (%) 21.33
    Particulars JUN 2025 (Values in Cr)
    Revenue 75.65
    Operating Expense 76.14
    Net Profit -0.23
    Net Profit Margin (%) -0.30
    Earnings Per Share (EPS) -0.74
    EBITDA 0.82
    Effective Tax Rate (%) 209.52
    Particulars MAR 2025 (Values in Cr)
    Revenue 71.20
    Operating Expense 71.46
    Net Profit -0.40
    Net Profit Margin (%) -0.56
    Earnings Per Share (EPS) -1.29
    EBITDA 0.02
    Effective Tax Rate (%) -11.11
    Particulars MAR 2026 (Values in Cr)
    Revenue 289.72
    Operating Expense 293.53
    Net Profit -3.31
    Net Profit Margin (%) -1.14
    Earnings Per Share (EPS) -10.72
    EBITDA -1.30
    Effective Tax Rate (%) -11.07
    Particulars MAR 2025 (Values in Cr)
    Revenue 285.86
    Operating Expense 276.94
    Net Profit 7.11
    Net Profit Margin (%) 2.48
    Earnings Per Share (EPS) 23.02
    EBITDA 11.21
    Effective Tax Rate (%) 28.00
    Particulars MAR 2024 (Values in Cr)
    Revenue 281.58
    Operating Expense 280.45
    Net Profit 2.16
    Net Profit Margin (%) 0.76
    Earnings Per Share (EPS) 7.00
    EBITDA 3.86
    Effective Tax Rate (%) 14.28
    Particulars MAR 2023 (Values in Cr)
    Revenue 310.65
    Operating Expense 288.59
    Net Profit 16.63
    Net Profit Margin (%) 5.35
    Earnings Per Share (EPS) 53.83
    EBITDA 24.40
    Effective Tax Rate (%) 26.18
    Particulars MAR 2022 (Values in Cr)
    Revenue 221.75
    Operating Expense 198.78
    Net Profit 17.18
    Net Profit Margin (%) 7.74
    Earnings Per Share (EPS) 55.62
    EBITDA 24.86
    Effective Tax Rate (%) 27.20
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 232.39
    ROE % 10.39
    ROCE % 13.60
    Total Debt to Total Equity 0.13
    EBITDA Margin 3.92
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 210.37
    ROE % 1.98
    ROCE % 2.83
    Total Debt to Total Equity 0.21
    EBITDA Margin 1.01
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 204.37
    ROE % 30.25
    ROCE % 34.91
    Total Debt to Total Equity 0.24
    EBITDA Margin 7.85
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 151.54
    ROE % 44.94
    ROCE % 52.32
    Total Debt to Total Equity 0.21
    EBITDA Margin 11.22
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 95.92
    ROE % 19.76
    ROCE % 23.90
    Total Debt to Total Equity 0.34
    EBITDA Margin 4.46
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 0.16
    Total Assets 121.49
    Total Liabilities 121.49
    Total Equity 71.80
    Share Outstanding 0
    Price to Book Ratio 1.35
    Return on Assets (%) 5.85
    Return on Capital (%) 8.7
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 9.73
    Total Assets 121.73
    Total Liabilities 121.73
    Total Equity 64.99
    Share Outstanding 0
    Price to Book Ratio 1.59
    Return on Assets (%) 1.77
    Return on Capital (%) 2.94
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 11.89
    Total Assets 116.58
    Total Liabilities 116.58
    Total Equity 63.14
    Share Outstanding 0
    Price to Book Ratio 1.82
    Return on Assets (%) 14.26
    Return on Capital (%) 20.33
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 14.70
    Total Assets 84.61
    Total Liabilities 84.61
    Total Equity 46.82
    Share Outstanding 0
    Price to Book Ratio 3.20
    Return on Assets (%) 20.31
    Return on Capital (%) 31.62
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 2.50
    Total Assets 57.39
    Total Liabilities 57.39
    Total Equity 29.63
    Share Outstanding 0
    Price to Book Ratio 1.42
    Return on Assets (%) 9.29
    Return on Capital (%) 13.88
    Particulars MAR 2025 (Values in Cr)
    Net Income 9.88
    Cash from Operations -8.63
    Cash from Investing 0.00
    Cash from Financing 0.47
    Net change in Cash -9.61
    Free Cash Flow -8.13
    Particulars MAR 2024 (Values in Cr)
    Net Income 2.52
    Cash from Operations 12.37
    Cash from Investing -0.40
    Cash from Financing -11.20
    Net change in Cash -2.19
    Free Cash Flow 13.04
    Particulars MAR 2023 (Values in Cr)
    Net Income 22.53
    Cash from Operations 0.06
    Cash from Investing -3.00
    Cash from Financing 9.59
    Net change in Cash -2.84
    Free Cash Flow 1.52
    Particulars MAR 2022 (Values in Cr)
    Net Income 23.60
    Cash from Operations 19.00
    Cash from Investing -1.06
    Cash from Financing -1.94
    Net change in Cash 14.46
    Free Cash Flow 20.28
    Particulars MAR 2021 (Values in Cr)
    Net Income 7.34
    Cash from Operations 7.05
    Cash from Investing -2.92
    Cash from Financing -1.88
    Net change in Cash -0.01
    Free Cash Flow 9.78
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 31.51 13.02 1.52 241.47 23.12 38.85
    BLISS GVS PHARMA LTD 492.50 39.98 4.37 5223.27 118.35 495.00
    CIPLA LTD 1440.30 30.57 3.37 116353.96 1165.55 1672.20
    FERMENTA BIOTECH LIMITED 365.50 16.12 2.64 1075.70 256.40 399.00
    GLAXOSMITHKLINE PHARMA LT 2358.85 41.53 17.62 39960.34 2088.00 3500.00
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 31.51 22.03 4.05 241.47 23.12 38.85
    AMRUTAJAN HEALTH LTD 538.05 24.12 4.20 1555.54 490.00 789.95
    ASTRAZENECA PHARMA INDIA LTD. 8382.65 109.48 24.01 20956.63 7630.00 9850.00
    BLISS GVS PHARMA LTD 492.50 53.13 4.52 5223.27 118.35 495.00

    SAMRAT PHARMACHEM LTD. shareholding pattern

    Holding
    47.67%
    49.09%
    3.23%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    SAMRAT PHARMACHEM LTD. Technicals Summary

    • EMA & SMA
    • Resistance and Support
    • Delivery and Volume
    • Beta
    • Price Change Analysis
    223.30 2.99 redarrow
    red-green-graph indicator
    2 Bearish
    14 Bullish
    • 5 Days 209.00
    • 26 Days 208.40
    • 10 Days 206.60
    • 50 Days 210.60
    • 12 Days 206.60
    • 100 Days 218.30
    • 20 Days 207.60
    • 200 Days 244.60
    215.60 PIVOT
    First Support 213.20 First Resistance 219.20 Second Support 209.60 Second Resistance 221.60 Third Support 207.20 Third Resistance 225.20
    RSI 57.67 ADX 18.87 MACD -1.81 Williams % R -5.37 Commodity Channel Index (CCI) 78.70
    Date 2026-06-25 Week 3078.00 Same Day 2437.00 Month 3055.00
    1 Year 0.65 3 Year 0.66
    Over 1 Month
    -6.65% down
    Over 1 Year
    -36.69% down
    Over 3 Months
    5.73% down
    Over 3 Years
    -20.61% down
    Over 6 Months
    -5.94% down
    Over 5 Years
    -2.29% down

    SAMRAT PHARMACHEM LTD. Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    18 Sep 2025 1.0 Final 18 Sep 2025 Equity shares
    19 Sep 2024 1.0 Final 19 Sep 2024 Equity shares
    18 Sep 2023 1.0 Final 18 Sep 2023 Equity shares
    22 Sep 2022 1.0 Final 23 Sep 2022 Equity shares

    Top Gainers

    Top Losers

    stock
    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Samrat Pharmachem Ltd?

    Answer Field

    Samrat Pharmachem Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 223.30 as on Jun 29 2026 03:29 PM.

    What is the Market Cap of Samrat Pharmachem Ltd Share?

    Answer Field

    The market cap of Samrat Pharmachem Ltd for NSE ₹ 0.00 & for BSE ₹ 69.00 as on Jun 29 2026 03:29 PM.

    What is the 52 Week High and Low of Samrat Pharmachem Ltd?

    Answer Field

    The 52 Week High and Low of Samrat Pharmachem Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 389.00 and ₹ 190.00.

    What is 1 year return for Samrat Pharmachem Ltd?

    Answer Field

    The 1 year returns on the stock has been -36.69%.

    What is the P/E Ratio of Samrat Pharmachem Ltd Share?

    Answer Field

    As on Jun 29 2026 03:29 PM the price-to-earnings (PE) ratio for Samrat Pharmachem Ltd share is -20.22.

    What is the PB ratio of Samrat Pharmachem Ltd Share?

    Answer Field

    As on Jun 29 2026 03:29 PM, the price-to-book (PB) ratio for Samrat Pharmachem Ltd share is 220.66.

    How to Buy Samrat Pharmachem Ltd Share?

    Answer Field

    You can trade in Samrat Pharmachem Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Samrat Pharmachem Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Samrat Pharmachem Ltd shares on the Bajaj Broking app, follow these steps:

    • Login to the Bajaj Broking App

    • Click on the Search Icon

    • Search “Samrat Pharmachem Ltd”

    • Click on the BUY icon

    • Place a buy order specifying the desired quantity of shares.

    • Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |